The dexamethasone suppression test in patients with mood disorders

Area of Science:

• Psychiatry
• Neuroendocrinology
• Mood Disorders

Background:

• The endogenous/nonendogenous mood disorder dichotomy is a key classification in psychiatry.
• The dexamethasone suppression test (DST) has been investigated as a biological marker for mood disorders.
• Previous research has explored the DST's utility in differentiating mood disorder subtypes.

Purpose of the Study:

• To validate the endogenous/nonendogenous mood disorder dichotomy using the DST.
• To assess the relationship between other mood disorder subtypes and DST results.
• To identify factors contributing to DST status and evaluate cortisol measurement sensitivities.

Main Methods:

• 487 adult inpatients and outpatients with unipolar or bipolar disorder underwent the 1.0-mg DST.
• Nonsuppression was defined as post-dexamethasone cortisol levels exceeding 4.0 micrograms/dL.
• Cortisol levels were measured at various time points post-dexamethasone administration.

Main Results:

• Dexamethasone nonsuppression rates were higher in endogenous depressions (35.2% outpatients, 61.5% inpatients) compared to nonendogenous depressions (9.0% outpatients, 18.5% inpatients).
• The DST demonstrated a sensitivity of 46.2% and specificity of 89.9% for differentiating endogenous from nonendogenous major depressive episodes.
• Weight loss, gender, and symptom severity had minimal impact on DST status; combined 4 p.m. and 11 p.m. cortisol samples detected 91.0% of abnormal inpatient DST results.

Conclusions:

• The Research Diagnostic Criteria (RDC) endogenous/nonendogenous dichotomy is validated by the DST.
• The DST serves as a useful biological marker for distinguishing between endogenous and nonendogenous mood disorders.
• Optimized cortisol sampling strategies can enhance the DST's detection of nonsuppression.